KWD
MCID: KWS002
MIFTS: 70

Kawasaki Disease (KWD) malady

Categories: Genetic diseases, Rare diseases, Cardiovascular diseases, Bone diseases, Immune diseases

Aliases & Classifications for Kawasaki Disease

About this section

Aliases & Descriptions for Kawasaki Disease:

Name: Kawasaki Disease 52 11 48 25 54 70 50 38 2 13
Mucocutaneous Lymph Node Syndrome 11 48 24 25 54 70 39 68
Acute Febrile Mucocutaneous Lymph Node Syndrome 11 25 27
Infantile Polyarteritis 24 70 68
Kawasaki Syndrome 48 25 2
Kawasaki Disease, Susceptibility to 24 12
 
Kd 25 2
Acute Febrile Mcls 11
Kawasaki's Disease 11
Mlns 11
Kwd 70

Characteristics:

Orphanet epidemiological data:

54
kawasaki disease:
Inheritance: Multigenic/multifactorial; Age of onset: Adolescent,Adult,Childhood,Infancy; Age of death: normal life expectancy

Classifications:



External Ids:

OMIM52 611775
Disease Ontology11 DOID:13378
ICD1030 M30.3
ICD9CM32 446.1
MeSH39 D009080
NCIt45 C34825
Orphanet54 ORPHA2331
ICD10 via Orphanet31 M30.3

Summaries for Kawasaki Disease

About this section
OMIM:52 Kawasaki disease is an acute, self-limited vasculitis of infants and children characterized by prolonged fever... (611775) more...

MalaCards based summary: Kawasaki Disease, also known as mucocutaneous lymph node syndrome, is related to hepatitis and pyelonephritis, and has symptoms including angina pectoris, angina pectoris and chest pain. An important gene associated with Kawasaki Disease is ITPKC (Inositol-Trisphosphate 3-Kinase C), and among its related pathways are Cell adhesion_ECM remodeling and Validated transcriptional targets of AP1 family members Fra1 and Fra2. Affiliated tissues include body, lymph node and heart, and related mouse phenotypes are neoplasm and liver/biliary system.

NIH Rare Diseases:48 Kawasaki disease is a disease that involves inflammation of the blood vessels. it is typically diagnosed in young children, but older children and adults can also develop this condition. kawasaki disease begins with a fever that lasts at least five days. other classic symptoms may include red eyes, lips, and mouth; rash; swollen and red hands and feet; and swollen lymph nodes. sometimes the disease affects the coronary arteries which carry oxygen-rich blood to the heart, which can lead to serious heart problems. kawasaki disease occurs most often in people of asian and pacific island descent. the cause of kawasaki disease is unknown. an infection along with genetic factors may be involved. treatment includes intravenous gamma globulin and high doses of aspirin in a hospital setting. prognosis is generally very good, but in cases of heart complications it depends on the severity of the coronary disease.  last updated: 3/9/2017

UniProtKB/Swiss-Prot:70 Kawasaki disease: An acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy.

MedlinePlus:38 Kawasaki disease is a rare childhood disease. it makes the walls of the blood vessels in the body become inflamed. it can affect any type of blood vessel, including the arteries, veins, and capillaries. no one knows what causes kawasaki disease. symptoms include high fever that lasts longer than 5 days swollen lymph nodes in the neck a rash on the mid-section and genital area red, dry, cracked lips and a red, swollen tongue red, swollen palms of the hands and soles of the feet redness of the eyes kawasaki disease can't be passed from one child to another. there is no single test. to diagnose it, doctors look at the signs and symptoms. they may also use an echocardiogram or other tests. it is mainly treated with medicines. rarely, medical procedures and surgery also may be used for children whose coronary arteries are affected. kawasaki disease can't be prevented. however, most children who develop the disease fully recover - usually within weeks of getting signs and symptoms. further problems are rare. nih: national heart, lung, and blood institute

CDC:2 Kawasaki disease (KD), also known as Kawasaki syndrome, is an acute febrile illness of unknown cause that primarily affects children younger than 5 years of age. The disease was first described in Japan by Tomisaku Kawasaki in 1967, and the first cases outside of Japan were reported in Hawaii in 1976. Clinical signs include fever, rash, swelling of the hands and feet, irritation and redness of the whites of the eyes, swollen lymph glands in the neck, and irritation and inflammation of the mouth, lips, and throat.

Genetics Home Reference:25 Kawasaki disease is a sudden and time-limited (acute) illness that affects infants and young children. Affected children develop a prolonged fever lasting several days, a skin rash, and swollen lymph nodes in the neck (cervical lymphadenopathy). They also develop redness in the whites of the eyes (conjunctivitis) and redness (erythema) of the lips, lining of the mouth (oral mucosa), tongue, palms of the hands, and soles of the feet.

Disease Ontology:11 A lymphadenitis characterized by swelling of cervical lymph nodes in infants and young children and inflammation of medium-sized blood vessels located in body, has symptom fever, has symptom congestion of ocular conjunctivae, has symptom reddening of lips, has symptom reddening of oral cavity, has symptom protuberance of tongue papillae and has symptom edema of extremities.

Wikipedia:71 Kawasaki disease, also known as mucocutaneous lymph node syndrome, is a disease in which blood vessels... more...

Related Diseases for Kawasaki Disease

About this section

Diseases related to Kawasaki Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 359)
idRelated DiseaseScoreTop Affiliating Genes
1hepatitis29.7IL10, IL6, TNF
2pyelonephritis29.6CRP, IL10, NPPB, TNF
3congestive heart failure29.1IL10, IL6, MBL2, SELL, TNF
4histiocytosis28.7CRP, ELANE, HSPD1, IL6, MMP3, MMP9
5rheumatoid arthritis28.6CCL2, CRP, HSPD1, IL10, IL6, MMP3
6myocardial infarction28.3ADM, ALB, CCL2, CRP, IL10, IL6
7abl1 kd-related altered drug metabolism11.8
8macrophage activation syndrome11.2
9spinal and bulbar muscular atrophy of kennedy10.9
10malignant hyperthermia susceptibility 110.8
11zap-70 deficiency10.8
12kniest dysplasia10.8
13aneurysm10.6
14coronary artery aneurysm10.5
15congenital dyserythropoietic anemia10.4ALB, TNF
16coronary aneurysm10.4
17pyridoxal 5'-phosphate-dependent epilepsy10.4IL10, TNF
18right atrium familial dilatation10.3MMP3, MMP9
19vps11-related autosomal recessive hypomyelinating leukodystrophy10.3IL6, TNF
20swine influenza10.3CRP, IL6, TNF
21central epithelioid sarcoma10.3CRP, MMP9, TNF
22human immunodeficiency virus infectious disease10.3CRP, IL6, TNF
23cataract10.3ALB, CRP, TNF
24cicatricial lagophthalmos10.3CRP, IL6, TNF
25tubular renal disease-cardiomyopathy syndrome10.3IL10, TNF
26shoulder impingement syndrome10.3ALB, CRP, IL6
27benign neonatal seizures10.3CRP, IL6, TNF
28leukoplakia of vagina10.3IL6, MMP9, TNF
29hypertropia10.3ALB, CRP, TNF
30mikulicz disease10.3ALB, IL6, TNF
31transient tic disorder10.3IL10, IL6, TNF
32neonatal hypoxic and ischemic brain injury10.3IL10, IL6, MMP9
33neuropathy10.3CRP, IL6, TNF
34cyclosporiasis10.3IL10, IL6, TNF
35hypoparathyroidism-retardation-dysmorphism syndrome10.3IL10, IL6, TNF
36conduct disorder10.3IL10, IL6, TNF
37gastric dilatation10.3IL10, IL6, TNF
38urticaria10.3ALB, CRP, TNF
39multiple mitochondrial dysfunctions syndrome10.3CRP, IL10, IL6
40rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies10.3IL10, IL6, TNF
41gonococcal endophthalmia10.3IL10, IL6, TNF
42ectodermal dysplasia bartalos type10.3IL10, IL6, TNF
43primary ciliary dyskinesia10.3IL10, IL6, TNF
44neurotic disorder10.3FCGR2A, IL10, TNF
45toxic myocarditis10.3CRP, IL6, NPPB
46hyperlipoproteinemia type iv10.3ALB, CRP, IL6
47bladder sarcoma10.3ALB, IL6, TNF
48steroid dehydrogenase deficiency dental anomalies10.3CCL2, IL6, TNF
49glucosephosphate dehydrogenase deficiency10.3ALB, IL6, NPPB
50intracranial arteriosclerosis10.3IL6, NPPB, TNF

Graphical network of the top 20 diseases related to Kawasaki Disease:



Diseases related to kawasaki disease

Symptoms & Phenotypes for Kawasaki Disease

About this section


Clinical features from OMIM:

611775

Symptoms:

 11 (show all 6)
  • fever
  • congestion of ocular conjunctivae
  • reddening of lips
  • reddening of oral cavity
  • protuberance of tongue papillae
  • edema of extremities

Human phenotypes related to Kawasaki Disease:

 54 64 (show all 37)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 proteinuria64 54 Very frequent (99-80%) HP:0000093
2 conjunctivitis64 54 Very frequent (99-80%) HP:0000509
3 skin rash64 54 Very frequent (99-80%) HP:0000988
4 vasculitis64 54 Very frequent (99-80%) HP:0002633
5 lymphadenopathy64 54 Very frequent (99-80%) HP:0002716
6 erythema64 54 Very frequent (99-80%) HP:0010783
7 recurrent pharyngitis64 54 Very frequent (99-80%) HP:0100776
8 cheilitis64 54 Very frequent (99-80%) HP:0100825
9 glossitis64 54 Frequent (79-30%) HP:0000206
10 edema64 54 Frequent (79-30%) HP:0000969
11 arthritis64 54 Frequent (79-30%) HP:0001369
12 abnormality of the heart valves64 54 Frequent (79-30%) HP:0001654
13 pericarditis64 54 Frequent (79-30%) HP:0001701
14 fever64 54 Frequent (79-30%) HP:0001945
15 leukocytosis64 54 Frequent (79-30%) HP:0001974
16 diarrhea64 54 Frequent (79-30%) HP:0002014
17 abdominal pain64 54 Frequent (79-30%) HP:0002027
18 fatigue64 54 Frequent (79-30%) HP:0012378
19 abnormality of nail color64 54 Frequent (79-30%) HP:0100643
20 ptosis64 54 Occasional (29-5%) HP:0000508
21 irritability64 54 Occasional (29-5%) HP:0000737
22 jaundice64 54 Occasional (29-5%) HP:0000952
23 cholecystitis64 54 Occasional (29-5%) HP:0001082
24 meningitis64 54 Occasional (29-5%) HP:0001287
25 congestive heart failure64 54 Occasional (29-5%) HP:0001635
26 nausea and vomiting64 54 Occasional (29-5%) HP:0002017
27 migraine64 54 Occasional (29-5%) HP:0002076
28 arthralgia64 54 Occasional (29-5%) HP:0002829
29 dilatation of the ascending aorta64 54 Occasional (29-5%) HP:0005111
30 interstitial pulmonary disease54 Occasional (29-5%)
31 cranial nerve paralysis64 54 Occasional (29-5%) HP:0006824
32 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis64 54 Occasional (29-5%) HP:0011658
33 arrhythmia64 54 Occasional (29-5%) HP:0011675
34 hepatitis64 54 Occasional (29-5%) HP:0012115
35 myocarditis64 54 Occasional (29-5%) HP:0012819
36 aseptic leukocyturia64 54 Occasional (29-5%) HP:0100586
37 interstitial pulmonary abnormality64 HP:0006530

UMLS symptoms related to Kawasaki Disease:


angina pectoris, chest pain, edema, exanthema, pruritus

MGI Mouse Phenotypes related to Kawasaki Disease according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.1ALB, ELANE, IL10, IL6, MMP9, MYD88
2MP:00053708.1ADM, ALB, IL10, IL6, SELE, SELL
3MP:00053857.8ADM, CRP, IL10, IL6, MMP9, MYD88
4MP:00053797.7ADM, ALB, IL10, IL6, ITPKC, MYD88
5MP:00053887.1ADM, IL10, IL6, MMP9, MYD88, SELE
6MP:00053766.2ADM, ALB, CRP, ELANE, IL10, IL6
7MP:00053976.2ADM, ELANE, FCGR2A, IL10, IL6, ITPKC
8MP:00053875.8ADM, CCL2, CRP, ELANE, FCGR2A, IL10

Drugs & Therapeutics for Kawasaki Disease

About this section

Drugs for Kawasaki Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 487)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CilostazolapprovedPhase 410673963-72-12754
Synonyms:
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
73963-72-1
89332-50-3
AC-4334
AC1L1EE2
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRN 3632107
BSPBio_002759
C 0737
C045645
C0737_SIGMA
C20H27N5O2
CHEBI:31401
CHEMBL799
CID2754
CL23867
CPD000058428
Cilostazol (JP15/USAN/INN)
Cilostazol [INN:JAN]
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
D01896
DB01166
EU-0100218
HMS1922N15
HMS2093M14
KBio3_002259
KBioGR_001184
 
LS-142693
Lopac-C-0737
Lopac0_000218
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
NCGC00015207-01
NCGC00015207-02
NCGC00015207-06
NCGC00015207-10
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
OPC 13013
OPC 21
OPC-13013
OPC-21
Otsuka brand of cilostazol
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
S1294_Selleck
SAM001246734
SAM001247085
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
TL8005113
Tocris-1692
UNII-N7Z035406B
ZINC01552174
cilostazol
2
Aspirinapproved, vet_approvedPhase 4, Phase 3, Phase 2115250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide acetylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
 
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
acide 2-(acétyloxy)benzoïque
acide acétylsalicylique
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
salicylic acid acetate
ácido acetilsalicílico
3
NorepinephrineapprovedPhase 4, Phase 3, Phase 269951-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
LT03330026
 
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Nor-adrenaline
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
4
EmpagliflozinapprovedPhase 4, Phase 3133864070-44-0
Synonyms:
 
(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
5
DopamineapprovedPhase 4, Phase 2, Phase 3383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
6
AmlodipineapprovedPhase 4, Phase 349688150-42-92162
Synonyms:
()-Amlodipine
(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine
2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)
3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl ( -)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat
3-Ethyl-5-methyl ( -)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
88150-42-9
88150-47-4 (maleate (1:1))
AC-4535
AC1L1D26
AC1Q32ZS
AMLODIPINE BASE
AMVAZ
Ambap88150-42-9
Amlocard
Amlodipine
Amlodipine (INN)
Amlodipine Benzenesulfonate
Amlodipine Besilate
Amlodipine Besylate
Amlodipine Free Base
Amlodipine [INN:BAN]
Amlodipine besilate
Amlodipine besylate
Amlodipine free base
Amlodipino
Amlodipino [Spanish]
Amlodipinum
Amlodipinum [Latin]
Amlodis
Amlopres
Amlor
 
Amvaz
BIDD:GT0810
BRD-A22032524-074-02-4
BRD-A22032524-074-03-2
BSPBio_002727
C06825
CHEBI:2668
CHEMBL1491
CID2162
CPD000469198
Coroval
D07450
DB00381
HMS2052N03
HMS2089H07
I14-0798
Intervask
Istin
KBio3_001947
KBioGR_001643
LS-131183
Lipinox
Lotrel
MLS001401409
MolPort-001-792-963
NCGC00165957-01
NCGC00165957-02
NCGC00165957-03
Norvasc
Norvasc (TN)
Pelmec
R,S)-Amlodipine
Racemic Amlodipine
SAM001246705
SMR000469198
SPBio_000351
Spectrum2_000486
Spectrum3_001004
Spectrum4_001132
Spectrum5_001550
UK-4834011
UNII-1J444QC288
amlodipine
7
Telmisartanapproved, investigationalPhase 4, Phase 3268144701-48-465999
Synonyms:
144701-48-4
2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
4'-((4-mehtyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimmidazolyl)methyl)-2-biphenylcarboxylic acid
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'h-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
AC-2013
AC1L24EB
AC1Q5U7O
Abbott brand of telmisartan
BAY-68-9291
BAY68-9291
BIBR 277
BIBR 277SE
BIBR-277
BIBR-277-SE
BIBR-277SE
BIDD:GT0365
BRD-K73999723-001-02-2
BSPBio_002738
Bay 68-9291
Bio-0103
Boehringer Ingelheim brand of telmisartan
C07710
C084178
C33H30N4O2
CHEBI:9434
CHEMBL1017
CID65999
CPD000466326
D00627
DB00966
Glaxo Wellcome brand of telmisartan
GlaxoSmithKline brand of telmisartan
 
HMS1922P07
HMS2051P16
HMS2090P17
HMS2093M22
HSDB 7590
I06-0281
KBio3_001958
KBioGR_001842
Kinzal
Kinzalmono
L001035
LS-44263
MLS000759432
MLS001076687
Micardis
Micardis (TN)
Micardis HCT
Micardis, Targit, Temax, BIBR277, Telmisartan
MolPort-003-666-621
NCGC00095150-01
NCGC00095150-02
NCGC00095150-03
Pritor
S1738_Selleck
SAM001246602
SMR000466326
SPBio_002131
SPECTRUM1505261
STK624049
Spectrum2_001976
Spectrum3_001089
Spectrum4_001261
Spectrum5_001053
TL8000991
Telmisartan
Telmisartan (JAN/USAN/INN)
Telmisartan [USAN:INN]
UNII-U5SYW473RQ
YM-086
telmisartan
8
Pregabalinapproved, illicit, investigationalPhase 4, Phase 3361148553-50-85486971
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3-Isobutyl gaba
3-isobutyl GABA
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
CI-1008
CID5486971
 
D02716
DB00230
FT-0080911
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregablin
S-(+)-3-isobutylgaba
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
9
Valsartanapproved, investigationalPhase 4295137862-53-460846
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
137862-53-4
AC-4543
AC1L1U1M
AC1Q5QIK
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
BRD-K45158365-001-02-3
BSPBio_003501
Bio-0796
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
 
Kalpress
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
LS-161334
Lacer brand of valsartan
MLS000759423
MLS001424088
Miten
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Nisis
Nisis||
Novartis brand of valsartan
Provas
S1894_Selleck
SAM001246581
SMR000466318
SPBio_001260
SPECTRUM1505209
Sanol brand of valsartan
Schwarz brand of valsartan
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Spectrum_001796
TL8000869
Tareg
UNII-80M03YXJ7I
Vals
Valsarran
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
valsartan
walsartan
|Tareg
10
GalantamineapprovedPhase 4106357-70-09651, 908828, 9651
Synonyms:
(-)-Galanthamine
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
1551-02-6
1953-04-4
1dx6
1qti
357-70-0
4-27-00-02184 (Beilstein Handbook Reference)
736-79-8
AC-20240
AC1L1TIM
BIDD:GT0517
BPBio1_000480
BRD-K49481516-004-03-5
BRD-K49481516-004-04-3
BRN 0093736
BSPBio_000436
BSPBio_003416
C08526
CHEBI:42944
CHEMBL659
CID9651
D04292
DivK1c_000590
GNT
Galantamin
Galantamina
Galantamina [INN-Spanish]
Galantamine
Galantamine (USAN/INN)
Galantamine [USAN:INN]
Galantaminum
Galantaminum [INN-Latin]
Galanthamine
Galanthamine hydrobromide
Galanthaminum
 
HMS2089H03
HSDB 7361
IDI1_000590
InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
Jilkon
KBio1_000590
KBio2_001751
KBio2_004319
KBio2_006887
KBio3_002636
KBioGR_001417
KBioSS_001751
LS-71039
Lycoremin
Lycoremine
MolPort-002-521-885
NCGC00024731-02
NINDS_000590
NSC 100058
Prestwick0_000588
Prestwick1_000588
Prestwick2_000588
Prestwick3_000588
Probes1_000055
Probes2_000395
Razadyne ER
Reminyl
Reminyl (TN)
SDCCGMLS-0066737.P001
SMP1_000131
SPBio_002655
STOCK1N-46108
Spectrum3_001738
Spectrum4_000839
Spectrum5_001673
Spectrum_001271
UNII-0D3Q044KCA
galanthamine
11
LinagliptinapprovedPhase 4, Phase 3139668270-12-010096344
Synonyms:
(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
(R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
668270-12-0
BI 1356
BI-1356
BI-1356-BS
CHEBI:49403
 
CHEBI:499873
CHEMBL237500
CID 10096344
CID10096344
Linagliptin
Ondero
Tradjenta
Trajenta
12
Vildagliptinapproved, investigationalPhase 4, Phase 3157274901-16-56918537
Synonyms:
(2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile
(2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)- (9CI)
274901-16-5
AC1NQOUT
AC1OCFK2
C502012
CHEBI:253127
CHEMBL142703
CHEMBL319819
CID11077541
CID5251896
CID6918537
D07080
DB04876
EQUA
Equa
FT-0082760
Galvu
Galvus
I11-0029
 
Jalra
LAF 237
LAF-237
LAF237
LS-193227
NVP-LAF 237
NVP-LAF-237
NVP-LAF237
SBB066750
UNII-I6B4B2U96P
Vidagliptin (see Vildagliptin)
Vildagliptin
Vildagliptin (JAN/USAN/INN)
Xiliarx
equa
galvus
jalra
laf 237
laf237
nvp-laf-237
nvp-laf237
s
xiliarx
13
AlogliptinapprovedPhase 4, Phase 3, Phase 260850649-61-511450633
Synonyms:
2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile
850649-61-5
Alogliptin
Alogliptina
Alogliptine
 
Alogliptinum
CHEMBL376359
CID11450633
MolPort-005-933-065
SYR-322
UNII-JHC049LO86
14
DonepezilapprovedPhase 4, Phase 3, Phase 2286120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
15
Rivastigmineapproved, investigationalPhase 4, Phase 383123441-03-277991
Synonyms:
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
123441-03-2
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
AB1004572
AC1L2U92
BIDD:GT0316
C11766
CHEMBL636
CID77991
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
D03822
DB00989
ENA 713 free base
 
Ena 713 Free Base
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon
Exelon Patch
HMS2089H18
I06-2037
LS-172571
MolPort-003-666-662
NCGC00167531-01
Rivastigmine (JAN/USAN/INN)
Rivastigmine Hydrogen Tartrate
Rivastigmine [USAN:INN]
Rivastigmine hydrogen tartrate
SDZ 212-713
UNII-PKI06M3IW0
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
rivastigmine
16
TiclopidineapprovedPhase 4, Phase 347155142-85-35472
Synonyms:
5-((2-Chlorophenyl)methyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine
5-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
55142-85-3
AC-15204
AC1L1KFB
BIDD:PXR0169
BPBio1_000191
BRD-K00603606-003-03-4
BRN 1216802
BSPBio_000173
C07140
C14H14ClNS
CAS-53885-35-1
CHEBI:9588
CHEMBL833
CID5472
D08594
DB00208
EINECS 259-498-5
HMS2089I18
L001108
LS-152434
MLS001201825
MolPort-002-507-849
 
NCGC00016872-01
NCGC00016872-02
NCGC00024361-04
PCR 5332
Prestwick0_000047
Prestwick1_000047
Prestwick2_000047
Prestwick3_000047
SMR000641861
SPBio_002094
STK589340
STOCK5S-54105
Ticlid
Ticlopidin-Puren
Ticlopidin-Puren (TN)
Ticlopidina
Ticlopidina [INN-Spanish]
Ticlopidine (INN)
Ticlopidine HCL
Ticlopidine Hydrochloride
Ticlopidine [INN:BAN]
Ticlopidinum
Ticlopidinum [INN-Latin]
UNII-OM90ZUW7M1
UNM-0000345023
ZINC19594599
ticlopidine
17
Methylprednisoloneapproved, vet_approvedPhase 4119383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
18
Gabapentinapproved, investigationalPhase 430360142-96-33446
Synonyms:
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
AKOS000280865
Aclonium
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G-154
G0318
G154_SIGMA
GBN
GOE 2450
Gabapen
Gabapentin
Gabapentin (JAN/USAN/INN)
Gabapentin GR
Gabapentin Hexal
Gabapentin Stada
Gabapentin [USAN:INN:BAN]
Gabapentin-ratiopharm
Gabapentina
Gabapentine
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
 
Gabapentinum [INN-Latin]
Gabapetin
Go 3450
Goe-3450
HMS1570N03
HMS2089J03
HSDB 7364
Hexal brand of gabapentin
I06-0677
L000733
LS-7194
Lopac-G-154
Lopac0_000582
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NSC742194
Neurontin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
Novopharm brand of gabapentin
PMS-Gabapentin
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
Prestwick_151
S2133_Selleck
SMR000058311
SPBio_002822
STK598009
Serada
Stadapharm brand of gabapentin
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
gabapentin
gabapentin (Neurontin)
gabapentina
gabapentinium
ratiopharm brand of gabapentin
19
rituximabapprovedPhase 41692174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
20
Prednisoloneapproved, vet_approvedPhase 4119350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
21
SaxagliptinapprovedPhase 4, Phase 2, Phase 3127361442-04-811243969
Synonyms:
(1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile
(1S,5S)-2-[2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)- (9CI)
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-amino(3-hydroxytricyclo[3.3
361442-04-8
AC-6008
BMS 477118-11
BMS-477118
 
BMS-477118-11
CHEBI:460723
CHEMBL385517
CID11243969
DB06335
OPC-262
Onglyza
S1540_Selleck
Saxagliptin
Saxagliptin anhydrous
22
Clopidogrelapproved, nutraceuticalPhase 4, Phase 3, Phase 2778120202-66-6, 113665-84-260606
Synonyms:
( )-(S)-Clopidogrel
(+)-(S)-Clopidogrel
(+)-Clopidogrel
(S)-Clopidogrel
(S)-Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
113665-84-2
AC-19024
AC1L1TKZ
AC1Q41I9
BIDD:GT0284
BRD-K27721098-065-02-9
BSPBio_003211
C16H16ClNO2S
CGE
CHEBI:37941
CHEMBL1771
CID60606
CLOPIDOGREL SULFATE
CPD000550475
Clopidogrel
Clopidogrel (INN)
Clopidogrel (TN)
Clopidogrel [BAN:INN]
Clopidogrel [Ban:Inn]
Clopidogrel [INN:BAN]
Clopidogrel bisulfate
Clopidogrel bisulphate
Clopidogrel sulfate
Clopidogrelum
D07729
DB00758
DivK1c_000787
HMS2090O21
HMS502H09
HSDB 7430
IDI1_000787
 
Isocover
KBio1_000787
KBio2_000545
KBio2_003113
KBio2_005681
KBio3_002431
KBioGR_000689
KBioSS_000545
LS-172232
MLS001165708
MLS001195633
MLS001304711
Methyl (+)-(S)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetate
MolPort-002-885-817
MolPort-003-845-991
NCGC00163329-02
NINDS_000787
Plavix
Plavix (TN)
SAM002589956
SMR000550475
SPBio_000463
SR 25990
STK580572
STOCK5S-27782
Spectrum2_000512
Spectrum3_001606
Spectrum4_000175
Spectrum_000105
TL8000400
UNII-A74586SNO7
Zyllt
clopidogrel
clopidogrel, (+)(S)-isomer
methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
nchem.651-comp8
23Cyclooxygenase InhibitorsPhase 4, Phase 3, Phase 22870
24Fibrinolytic AgentsPhase 4, Phase 3, Phase 22388
25
SerotoninPhase 4, Phase 3, Phase 2362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
26AntiemeticsPhase 4, Phase 3, Phase 24022
27Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18402
28Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 25592
29Lipid Regulating AgentsPhase 4, Phase 2, Phase 12766
30Hypolipidemic AgentsPhase 4, Phase 2, Phase 12785
31Anticholesteremic AgentsPhase 4, Phase 2, Phase 12025
32Neuroprotective AgentsPhase 4, Phase 31716
33AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 112054
34Atorvastatin CalciumPhase 4, Phase 2, Phase 1760134523-03-8
35Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 4, Phase 2, Phase 11998
36glucocorticoidsPhase 4, Phase 3, Phase 25103
37Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 123689
38Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 3, Phase 24443
39HIV Protease InhibitorsPhase 4, Phase 3, Phase 2, Phase 15470
40
protease inhibitorsPhase 4, Phase 3, Phase 2, Phase 15471
Synonyms:
 
protease inhibitors
41Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 210729
42Anti-Asthmatic AgentsPhase 4, Phase 3, Phase 23488
43AntipyreticsPhase 4, Phase 3, Phase 21605
44Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 110956
45HormonesPhase 4, Phase 3, Phase 214415
46Hormone AntagonistsPhase 4, Phase 3, Phase 213180
47Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 213168
48Bronchodilator AgentsPhase 4, Phase 3, Phase 22965
49Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 110150
50AnalgesicsPhase 4, Phase 3, Phase 211733

Interventional clinical trials:

(show top 50)    (show all 406)
idNameStatusNCT IDPhase
1Sufficient Treatment of Peripheral Intervention by CilostazolUnknown statusNCT00912756Phase 4
2Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki DiseaseCompletedNCT01524939Phase 4
3Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular DiseaseCompletedNCT00190580Phase 4
4Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese PatientsCompletedNCT01325935Phase 4
5Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase InhibitorsCompletedNCT01529619Phase 4
6The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)CompletedNCT00250380Phase 4
7INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic NephropathyCompletedNCT00153088Phase 4
8PROs in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With PregabalinCompletedNCT02273908Phase 4
9Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese PatientsCompletedNCT01190007Phase 4
10A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)CompletedNCT02417935Phase 4
11A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki DiseaseRecruitingNCT02951234Phase 4
12The Preventive Implantation of Bioresorbable Vascular Scaffold on Functionally Insignificant Stenosis With Vulnerable Plaque CharacteristicsRecruitingNCT02316886Phase 4
13Low-dose Glucocorticoid Vasculitis Induction StudyRecruitingNCT02198248Phase 4
14Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes MellitusRecruitingNCT03014479Phase 4
15A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome PatientsRecruitingNCT03053427Phase 4
16Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)Active, not recruitingNCT01897532Phase 4
17Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RAActive, not recruitingNCT02589626Phase 4
18Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes MellitusActive, not recruitingNCT02589639Phase 4
19Study of Peretinoin for Suppressing Recurrence of HCV-positive HCCUnknown statusNCT01640808Phase 3
20S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck CancerUnknown statusNCT00336947Phase 3
21Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCCUnknown statusNCT01214343Phase 3
22Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised TrialCompletedNCT02298062Phase 3
23Different Doses of IVIG for Kawasaki DiseaseCompletedNCT02439996Phase 3
24A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki DiseaseCompletedNCT00162032Phase 3
25Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki DiseaseCompletedNCT00760435Phase 3
26Clinical Study of TA-650 in Patients With Refractory Kawasaki DiseaseCompletedNCT01596335Phase 3
27Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart NetworkCompletedNCT00132080Phase 3
28Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency DisordersCompletedNCT00157079Phase 3
29An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune ThrombocytopeniaCompletedNCT02063789Phase 3
30Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)CompletedNCT00001768Phase 3
31Acarbose and Secondary Prevention After Coronary StentingCompletedNCT00221156Phase 3
32Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)CompletedNCT01614886Phase 3
33Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.CompletedNCT02296138Phase 3
34A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease ParticipantsCompletedNCT02337738Phase 2, Phase 3
35Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00876694Phase 3
36Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00794157Phase 3
37A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease ParticipantsCompletedNCT02337764Phase 3
38Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01285492Phase 3
39Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD PatientsCompletedNCT02629965Phase 3
40Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01069289Phase 3
41Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT01047553Phase 3
42Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By SurgeryCompletedNCT00392899Phase 3
43A Phase 3 Study of SME3110 in Pediatric/Adolescent Subjects With Obsessive Compulsive DisorderCompletedNCT01933919Phase 3
44Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's DiseaseCompletedNCT01539031Phase 3
45Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EUCompletedNCT00628862Phase 3
46Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)CompletedNCT01441440Phase 3
47Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive DisorderCompletedNCT01355081Phase 3
48Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01431287Phase 3
49Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese PatientsCompletedNCT01119937Phase 3
50Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive DisorderCompletedNCT01395147Phase 3

Search NIH Clinical Center for Kawasaki Disease


Cochrane evidence based reviews: mucocutaneous lymph node syndrome

Genetic Tests for Kawasaki Disease

About this section

Genetic tests related to Kawasaki Disease:

id Genetic test Affiliating Genes
1 Acute Febrile Mucocutaneous Lymph Node Syndrome27
2 Kawasaki Disease, Susceptibility to24 ITPKC

Anatomical Context for Kawasaki Disease

About this section

MalaCards organs/tissues related to Kawasaki Disease:

36
Lymph node, Heart, Tongue, Eye, Skin, Endothelial, Testes

FMA organs/tissues related to Kawasaki Disease:

17
Body

Publications for Kawasaki Disease

About this section

Articles related to Kawasaki Disease:

(show top 50)    (show all 1101)
idTitleAuthorsYear
1
Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children. (28461824)
2017
2
Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment. (28089146)
2017
3
Prediction of Resistance to Intravenous Immunoglobulin in Children With Kawasaki Disease. (28062554)
2017
4
Observational study of Interleukin-21 (IL-21) does not distinguish Kawasaki disease from other causes of fever in children. (28427414)
2017
5
Elevated serum YKL-40 levels in patients with Kawasaki disease. (27881022)
2017
6
Evaluation of myocardial deformation in patients with Kawasaki disease using speckle-tracking echocardiography during mid-term follow-up - CORRIGENDUM. (28532518)
2017
7
TNF-I+ is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease. (28526535)
2017
8
High-dose aspirin for Kawasaki disease: outdated myth or effective aid? (28079513)
2017
9
Distinct Distribution of Immunocytes in a Retropharyngeal Lymphadenopathy Associated with Kawasaki Disease: A Case Study Compared with Tonsillitis. (28467980)
2017
10
Z-score of Mitral Annular Plane Systolic Excursion is a Useful Indicator of Evaluation of Left Ventricular Function in Patients with Acute-Phase Kawasaki Disease. (28456832)
2017
11
Allograft Inflammatory Factor-1 Links T-Cell Activation, Interferon Response, and Macrophage Activation in Chronic Kawasaki Disease Arteritis. (28505365)
2017
12
The serum concentration of soluble interleukin-2 receptor in patients with Kawasaki disease. (28081636)
2017
13
A Case of Hemophagocytic Lymphohistiocytosis and Kawasaki Disease: Concurrent or Overlapping Diagnoses? (28452857)
2017
14
Heart Transplantation in a Toddler with Cardiac Kawasaki Disease. (28473974)
2017
15
Vascular function long term after Kawasaki disease: another piece of the puzzle? (28446266)
2017
16
Association of PECAM-1 Gene Polymorphisms with Kawasaki Disease in Chinese Children. (28512385)
2017
17
Simultaneous development of Kawasaki disease following acute human adenovirus infection in monozygotic twins: A case report. (28511718)
2017
18
Reaction of the BCG Scar in the Acute Phase of Kawasaki Disease in Mexican Children. (28498302)
2017
19
Identifying genetic hypomethylation and upregulation of toll-like receptors in Kawasaki disease. (28061462)
2017
20
Pathogenetic determinants in Kawasaki disease: the haematological point of view. (28063205)
2017
21
Anti-inflammatory effect of resveratrol in human coronary arterial endothelial cells via induction of autophagy: implication for the treatment of Kawasaki disease. (28069066)
2017
22
Intravenous Immunoglobulin for the Treatment of Kawasaki Disease. (28079915)
2017
23
Atypical desquamation in a 2.5-year-old boy with Kawasaki disease: A case report. (28465804)
2017
24
Retrospective analysis of risk factors associated with Kawasaki disease in China. (28514726)
2017
25
Fever without a source: evolution of a diagnosis from Kawasaki disease to acute myelogenous leukaemia. (28478386)
2017
26
Novel Risk Assessment Tool for Immunoglobulin-Resistance in Kawasaki Disease: Application Using a Random Forest Classifier. (28441265)
2017
27
Mid-term Risk for Subclinical Atherosclerosis and Chronic Myocarditis in Children with Kawasaki Disease and Transient Coronary Abnormalities. (28512721)
2017
28
A plasma mir-125a-5p as a novel biomarker for Kawasaki disease and induces apoptosis in HUVECs. (28467514)
2017
29
Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker. (28417923)
2017
30
ST-elevation myocardial infarction in a young adult secondary to giant coronary aneurysm thrombosis: an important sequela of Kawasaki disease and a management challenge. (26791126)
2016
31
Suppressive influence of seasonal influenza epidemic on Kawasaki disease onset. (28049962)
2016
32
Medium- or Higher-Dose Acetylsalicylic Acid for Acute Kawasaki Disease and Patient Outcomes. (28043685)
2016
33
Kawasaki disease associated with Mycoplasma pneumoniae. (27609267)
2016
34
Usefulness of Single Photon Emission Computed Tomography/Computed Tomography Fusion-Hybrid Imaging to Evaluate Coronary Artery Disorders in Patients with a History of Kawasaki Disease. (27180792)
2016
35
Identification of Differentially Expressed Genes in Kawasaki Disease Patients as Potential Biomarkers for IVIG Sensitivity by Bioinformatics Analysis. (27160104)
2016
36
The different cutaneous presentations in three cases of Kawasaki disease as confounding factor of diagnosis. (27654745)
2016
37
One small step for exosomes, one giant leap for Kawasaki disease. (27132470)
2016
38
Systemic-onset juvenile idiopathic arthritis or incomplete Kawasaki disease: a diagnostic challenge. (27782865)
2016
39
Genome-Wide Association Study Identifies Novel Susceptibility Genes Associated with Coronary Artery Aneurysm Formation in Kawasaki Disease. (27171184)
2016
40
Soluble LR11 is a novel biomarker for vascular lesions late after Kawasaki disease. (26761773)
2016
41
Importance of anatomical dominance in the evaluation of coronary dilatation in Kawasaki disease. (27640521)
2016
42
Efficacy of Four Scoring Systems in Predicting Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease in a Children's Hospital in Beijing, North China. (28043682)
2016
43
Usefulness of anterior uveitis as an additional tool for diagnosing incomplete Kawasaki disease. (27186227)
2016
44
Crystalline keratopathy due to intravenous immunoglobulin in a 12-year-old girl with Kawasaki disease. (27667371)
2016
45
Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease. (27064036)
2016
46
Variations in ORAI1 Gene Associated with Kawasaki Disease. (26789410)
2016
47
Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. (27997519)
2016
48
Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities. (27610181)
2016
49
Myeloperoxidase genetic polymorphisms and susceptibility to Kawasaki disease in Taiwanese children. (26066543)
2016
50
Giant Coronary Aneurysms in a one-month-old Infant with Kawasaki Disease. (27641973)
2016

Variations for Kawasaki Disease

About this section

Expression for genes affiliated with Kawasaki Disease

About this section
Search GEO for disease gene expression data for Kawasaki Disease.

Pathways for genes affiliated with Kawasaki Disease

About this section

Pathways related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 39)
idSuper pathwaysScoreTop Affiliating Genes
19.7MMP3, MMP9, TIMP1
29.7CCL2, IL6, MMP9
39.6CRP, IL6, TNF
49.6CCL2, MMP9, MYD88, TIMP1
59.5CCL2, MMP9, SELE, TNF
6
Show member pathways
9.5CCL2, MMP3, MMP9, TIMP1
79.4CCL2, IL6, SELE, TNF
89.3ELANE, IL6, MMP9, TNF
99.3ELANE, IL6, MMP3, MMP9
109.3HSPD1, IL6, MYD88, TNF
119.3CCL2, IL6, MMP3, TNF
129.2IL10, IL6, TNF
139.2IL10, IL6, TNF
14
Show member pathways
9.2CCL2, IL6, MMP9, SELE, TNF
159.2CCL2, IL6, MMP9, TIMP1, TNF
16
Show member pathways
9.1ELANE, MMP3, MMP9, TIMP1, TNF
17
Show member pathways
9.1IL6, MMP3, MMP9, SELE, TNF
18
Show member pathways
9.1CCL2, IL6, MMP3, MMP9, TNF
199.1ELANE, MMP3, MMP9, SELE, SELL
209.0CCL2, IL10, IL6, TNF
21
Show member pathways
9.0ALB, CCL2, CRP, IL6, TNF
229.0IL10, IL6, MYD88, TNF
238.9HSPD1, IL10, IL6, TNF
248.9FCGR2A, IL10, MBL2
258.9CCL2, FCGR2A, IL6, MMP9, TNF
268.9CCL2, IL6, MMP3, MMP9, SELE, TNF
278.8IL10, IL6, SELL, TNF
28
Show member pathways
8.8FCGR2A, IL10, MYD88, TNF
298.7CCL2, IL10, IL6, TIMP1, TNF
30
Show member pathways
8.7CCL2, IL10, IL6, TIMP1, TNF
318.7IL10, IL6, MYD88, SELE, TNF
328.7FCGR2A, IL10, IL6, TNF
338.5CCL2, IL10, IL6, MYD88, SELE, TNF
348.3FCGR2A, IL10, IL6, SELL, TNF
358.2CCL2, IL10, IL6, MMP3, MMP9, TIMP1
368.2FCGR2A, HSPD1, IL10, IL6, MYD88, TNF
37
Show member pathways
8.1CCL2, IL10, IL6, MBL2, MMP9, MYD88
38
Show member pathways
8.0CCL2, IL10, IL6, MMP3, MMP9, MYD88
39
Show member pathways
6.0CCL2, CRP, ELANE, FCGR2A, IL10, IL6

GO Terms for genes affiliated with Kawasaki Disease

About this section

Cellular components related to Kawasaki Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00055766.4ADM, ALB, CCL2, CRP, ELANE, IL10
2extracellular spaceGO:00056155.4ADM, ALB, CCL2, CRP, ELANE, HSPD1

Biological processes related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 45)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of chemokine biosynthetic processGO:004508010.6MYD88, TNF
2opsonizationGO:000822810.6CRP, MBL2
3epithelial cell proliferation involved in salivary gland morphogenesisGO:006066410.6IL6, TNF
4positive regulation of interleukin-8 biosynthetic processGO:004541610.6ELANE, TNF
5negative regulation of chemokine biosynthetic processGO:004507910.6ELANE, IL6
6regulation of vascular endothelial growth factor productionGO:001057410.6CCL2, IL6
7leukocyte migration involved in inflammatory responseGO:000252310.5CCL2, ELANE, SELE
8monocyte chemotaxisGO:000254810.5CCL2, IL6, S100A12
9lipopolysaccharide-mediated signaling pathwayGO:003166310.5CCL2, MYD88, TNF
10positive regulation of MAP kinase activityGO:004340610.4ELANE, S100A12, TNF
11response to peptidoglycanGO:003249410.4IL6, MYD88
12negative regulation of lipid storageGO:001088810.4CRP, IL6, TNF
13humoral immune responseGO:000695910.4CCL2, IL6, TNF
14negative regulation of membrane protein ectodomain proteolysisGO:005104510.3IL10, TIMP1
15endothelial cell apoptotic processGO:007257710.3IL10, TNF
16acute-phase responseGO:000695310.3CRP, IL6, MBL2
17negative regulation of cytokine secretion involved in immune responseGO:000274010.3IL10, TNF
18response to heatGO:000940810.3CCL2, HSPD1, IL6
19positive regulation of heterotypic cell-cell adhesionGO:003411610.3IL10, TNF
20receptor biosynthetic processGO:003280010.2IL10, TNF
21extracellular matrix disassemblyGO:002261710.2ELANE, MMP3, MMP9, TIMP1
22positive regulation of NF-kappaB transcription factor activityGO:005109210.1IL6, MYD88, S100A12, TNF
23cellular response to estradiol stimulusGO:007139210.1CCL2, IL10, IL6
24response to activityGO:001482310.0CCL2, HSPD1, IL10
25positive regulation of vascular smooth muscle cell proliferationGO:190470710.0IL10, MMP9, TNF
26positive regulation of interleukin-6 productionGO:003275510.0HSPD1, IL6, MYD88, TNF
27positive regulation of smooth muscle cell proliferationGO:004866110.0ELANE, IL6, MYD88, TNF
28leukocyte migrationGO:00509009.9ELANE, MMP9, SELE, SELL, TNF
29response to yeastGO:00018789.8ELANE, IL6
30branching involved in labyrinthine layer morphogenesisGO:00606709.8ADM, IL10
31cellular response to lipopolysaccharideGO:00712229.8CCL2, IL10, IL6, TNF
32response to coldGO:00094099.7ADM, HSPD1, IL6
33neutrophil degranulationGO:00433129.6ELANE, FCGR2A, MMP9, S100A12, SELL
34defense response to bacteriumGO:00427429.4ELANE, IL10, MBL2, S100A12, TNF
35negative regulation of growth of symbiont in hostGO:00441309.3ELANE, IL10, MBL2, MYD88, TNF
36response to insulinGO:00328689.3ADM, IL10, IL6
37response to woundingGO:00096119.3ADM, CCL2, IL6
38positive regulation of apoptotic processGO:00430659.2ADM, HSPD1, IL6, MMP9, TNF
39agingGO:00075689.0ADM, CCL2, IL10, IL6, TIMP1
40defense response to Gram-positive bacteriumGO:00508308.9ADM, CRP, IL6, MBL2, MYD88, TNF
41inflammatory responseGO:00069548.9CCL2, CRP, IL10, IL6, MYD88, S100A12
42negative regulation of apoptotic processGO:00430668.8ALB, HSPD1, IL10, IL6, MMP9, MYD88
43response to organic substanceGO:00100338.7ADM, HSPD1, IL10, TIMP1, TNF
44response to glucocorticoidGO:00513848.6ADM, CCL2, HSPD1, IL10, IL6, TNF
45response to lipopolysaccharideGO:00324968.0ADM, CCL2, ELANE, HSPD1, IL10, IL6

Molecular functions related to Kawasaki Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1endopeptidase activityGO:000417510.5ELANE, MMP3, MMP9
2protease bindingGO:00020209.8ELANE, HSPD1, SELL, TIMP1, TNF
3cytokine activityGO:00051259.6CCL2, IL10, IL6, TIMP1, TNF
4receptor bindingGO:00051028.2ADM, CCL2, IL6, MBL2, MYD88, NPPB
5protein bindingGO:00055154.9ADM, ALB, CRP, ELANE, FCGR2A, HSPD1

Sources for Kawasaki Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet